Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: Pharmacokinetics, toxicity and preliminary efficacy

Cancer Chemotherapy and Pharmacology

Volumn 74, Issue 3, 2014, Pages 637-646

  Yang, Jianliang ^a   Shi, Yuankai ^a   Li, Chunlei ^b   Gui, Lin ^a   Zhao, Xi ^b   Liu, Peng ^a   Han, Xiaohong ^a   Song, Yuanyuan ^a   Li, Ning ^a   Du, Ping ^a   Zhang, Shuxiang ^a  

^a CANCER HOSPITAL   (China)

^b CSPC ZhongQi Pharmaceutical Technology Co Ltd   (China)

Author keywords

Efficacy; Pegylated liposomal mitoxantrone; Pharmacokinetics; Phase I clinical trial; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; MITOXANTRONE; PEGYLATED LIPOSOMAL MITOXANTRONE; PLM 60S; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ENCAPSULATION; ERYTHROPENIA; FEMALE; HUMAN; INFUSION RELATED REACTION; LEUKOPENIA; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RASH; SIDE EFFECT; SOLID TUMOR; SUSTAINED DRUG RELEASE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOLUME OF DISTRIBUTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; LIPOSOMES; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASMS; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84907597527     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-014-2523-8     Document Type: Article

References (20)

1. McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A et al (2000) Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37-41 (Pubitemid 32164595)
2. Gilligan T, Kantoff PW (2002) Chemotherapy for prostate cancer. Urology 60(3 Suppl 1):94-100 discussion 100
3. Lenk H, Muller U, Tanneberger S (1987) Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anti-cancer Res 7(6):1257-1264 (Pubitemid 18062730)
4. Fox EJ (2004) Mechanism of action of mitoxantrone. Neurology 63(12 Suppl 6):S15-S18
5. Seiter K (2005) Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4(2):219-234
6. Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56(5):747-756
7. Allen TM (1997) Liposomes. Opportunities in drug delivery. Drugs 54(Suppl 4):8-14
8. Gokhale PC, Pei J, Zhang C, Ahmad I, Rahman A, Kasid U (2001) Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res 21(5):3313-3321 (Pubitemid 34224233)
9. Li C, Cui J, Li Y, Wang C, Li Y, Zhang L, Zhang L, Guo W, Wang J, Zhang H, Hao Y, Wang Y (2008) Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. Eur J Pharm Sci 34(4-5):333-344
10. Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y (2008) Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 70(2):657-665
11. Lim HJ, Masin D, Madden TD, Bally MB (1997) Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566-573 (Pubitemid 27203116)
12. Pestalozzi BC, Vass A, Adam H, Horber DH, Schwendener RA, Sauter C (1995) Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Eur J Cancer 31A(6):1024
13. Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB (2000) Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337-345 (Pubitemid 30026391)
14. Li C, Zhao X, Deng C, Wang C, Wei N, Cui J (2014) Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect. Int J Pharm 460(1-2):165-172
15. Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire. Ann Oncol 20(12):1929-1935
16. Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37(1):1-3 (Pubitemid 32613627)
17. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579-586 (Pubitemid 350002966)
18. Pestalozzi B, Schwendener R, Sauter C (1992) Phase I/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3(6):445-449
19. Szebeni J (2001) Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit Rev Ther Drug Carrier Syst 18(6):567-606
20. Szebeni J, Muggia F, Gabizon A, Barenholz Y (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63(12):1020-1030